PURCHASE, N.Y., April 2, 2013 (GLOBE NEWSWIRE) -- MVC Capital, Inc. (NYSE:MVC) (the "Company"), a publicly traded business development company that makes private debt and equity investments, announced today the completed sale of a portfolio company, Summit Research Labs ("Summit"), a specialty chemical company that manufactures and markets antiperspirant actives globally, to an affiliate of One Rock Capital Partners, LLC.
MVC received gross equity proceeds of $66 million, realizing a gain of $50 million from the transaction, a $3.5 million premium to the last reported fair market value placed on Summit by the Company's Valuation Committee as of January 31, 2013. This transaction reflects a 31% gross IRR 1 for MVC since the time of its original investment in Summit in August 2006. The gross IRR includes all fees and distributions received from its equity position in Summit over the life of the investment. MVC also received $16.5 million in gross debt proceeds from its original $8.0 million second lien loan provided to Summit.
As part of the agreement, MVC provided Summit with a new, $22 million second lien loan, which matures in five and a half years."We are pleased to have finalized the sale of Summit and are proud to have helped the company become a leading global manufacturer of antiperspirant actives," said Michael Tokarz, Chairman and Portfolio Manager of MVC. "Our team looks forward to redeploying these proceeds into new yielding investments, which we believe will build additional value for our shareholders." "MVC will continue to maintain an active working relationship with Summit by providing a $22 million loan to support its growth objectives. We believe that Summit can continue to provide an excellent return for our shareholders," said Shivani Khurana, Director of Summit and Managing Director of TTGA, investment adviser to MVC Capital, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV